Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases

Current Protein and Peptide Science

Volumn 17, Issue 2, 2016, Pages 135-146

  Szelag, Malgorzata ^a   Wesoly, Joanna ^a   Bluyssen, Hans A R ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Biopolymers; Dimerization inhibition; DNA binding inhibition; Human diseases; Peptide aptamers; Peptides; Peptidomimetics; STAT signaling

Indexed keywords

ALPHA HELIX PEPTIDE ANALOG; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; LIPOPEPTIDE; NATURAL PRODUCT; NON PEPTIDE SMALL MOLECULE; ORGANOMETALLIC COMPOUND; PEPTIDE; PEPTIDE APTAMER; PEPTIDOMIMETIC AGENT; PHOSPHOPEPTIDE; PROTEIN TRANSDUCTION DOMAIN CONJUGATE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INDUCER; SPHINGOSINE KINASE INHIBITOR; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ALLERGY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL MEMBRANE PERMEABILITY; DIMERIZATION; DISEASES; DNA BINDING; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; INFECTION; METABOLIC ACTIVATION; NEOPLASM; OLIGOMERIZATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION;

AMINO ACID SEQUENCE; DISEASE; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PEPTIDOMIMETICS; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84958952773     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203716666151102103706     Document Type: Article

References (89)

1. Darnell, J. E., Jr.; Kerr, I. M.; Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, 264(5164), 1415-1421.
2. Sikorski, K.; Chmielewski, S.; Olejnik, A.; Wesoly, J. Z.; Heemann, U.; Baumann, M.; Bluyssen, H. STAT1 as a central mediator of IFNgamma and TLR4 signal integration in vascular dysfunction. JAKSTAT, 2012, 1(4), 241-249.
3. Levy, D. E.; Darnell, J. E., Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol., 2002, 3(9), 651-662.
4. Horvath, C. M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci. 2000, 25(10), 496-502.
5. Shuai, K.; Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol., 2003, 3(11), 900-911.
6. Bar-Natan, M.; Nelson, E. A.; Xiang, M.; Frank, D. A. STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT, 2012, 1(2), 55-64.
7. Frank, D. A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett., 2007, 251(2), 199-210.
8. El Kasmi, K. C.; Holst, J.; Coffre, M.; Mielke, L.; de Pauw, A.; Lhocine, N.; Smith, A. M.; Rutschman, R.; Kaushal, D.; Shen, Y.; Suda, T.; Donnelly, R. P.; Myers, M. G., Jr.; Alexander, W.; Vignali, D. A.; Watowich, S. S.; Ernst, M.; Hilton, D. J.; Murray, P. J. General nature of the STAT3-activated anti-inflammatory response. J. Immunol., 2006, 177(11), 7880-7888.
9. Kamran, M. Z.; Patil, P.; Gude, R. P. Role of STAT3 in cancer metastasis and translational advances. Biomed. Res. Int., 2013, 2013, 421821.
10. Sikorski, K.; Czerwoniec, A.; Bujnicki, J. M.; Wesoly, J.; Bluyssen, H. A. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev., 2011, 22(4), 211-219.
11. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 2009, 9(11), 798-809.
12. Benekli, M.; Baumann, H.; Wetzler, M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol. 2009, 27(26), 4422-4432.
13. Nelson, E. A.; Sharma, S. V.; Settleman, J.; Frank, D. A. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget, 2011, 2(6), 518-524.
14. Becker, S.; Groner, B.; Muller, C. W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature, 1998, 394(6689), 145-151.
15. Chen, X.; Vinkemeier, U.; Zhao, Y.; Jeruzalmi, D.; Darnell, J. E., Jr.; Kuriyan, J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell, 1998, 93(5), 827-839.
16. Mao, X.; Ren, Z.; Parker, G. N.; Sondermann, H.; Pastorello, M. A.; Wang, W.; McMurray, J. S.; Demeler, B.; Darnell, J. E., Jr.; Chen, X. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol. Cell, 2005, 17(6), 761-771.
17. Neculai, D.; Neculai, A. M.; Verrier, S.; Straub, K.; Klumpp, K.; Pfitzner, E.; Becker, S. Structure of the unphosphorylated STAT5a dimer. J. Biol. Chem., 2005, 280(49), 40782-40787.
18. Debnath, B.; Xu, S.; Neamati, N. Small molecule inhibitors of signal transducer and activator of transcription 3(Stat3) protein. J. Med. Chem., 2012, 55(15), 6645-6668.
19. Deng, J.; Grande, F.; Neamati, N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets, 2007, 7(1), 91-107.
20. Fagard, R.; Metelev, V.; Souissi, I.; Baran-Marszak, F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT, 2013, 2(1), e22882.
21. Furqan, M.; Akinleye, A.; Mukhi, N.; Mittal, V.; Chen, Y.; Liu, D. STAT inhibitors for cancer therapy. J. Hematol. Oncol., 2013, 6, 90.
22. Kortylewski, M.; Nechaev, S. Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver? Ther. Deliv., 2014, 5(3), 239-242.
23. Lavecchia, A.; Di Giovanni, C.; Novellino, E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr. Med. Chem., 2011, 18(16), 2359-2375.
24. Miklossy, G.; Hilliard, T. S.; Turkson, J. Therapeutic modulators of STAT signalling for human diseases. Nat. Rev. Drug Discov., 2013, 12(8), 611-629.
25. Timofeeva, O. A.; Tarasova, N. I. Alternative ways of modulating JAK-STAT pathway: Looking beyond phosphorylation. JAKSTAT, 2012, 1(4), 274-284.
26. Turkson, J.; Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 2000, 19(56), 6613-6626.
27. Sen, M.; Grandis, J. R. Nucleic acid-based approaches to STAT inhibition. JAKSTAT, 2012, 1(4), 285-291.
28. Siveen, K. S.; Sikka, S.; Surana, R.; Dai, X.; Zhang, J.; Kumar, A. P.; Tan, B. K.; Sethi, G.; Bishayee, A. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim. Biophys. Acta, 2014, 1845(2), 136-154.
29. Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(13), 4700-4705.
30. Mankan, A. K.; Greten, F. R. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin. Investig. Drugs, 2011, 20(9), 1263-1275.
31. Page, B. D.; Ball, D. P.; Gunning, P. T. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin. Ther. Pat., 2011, 21(1), 65-83.
32. Trecul, A.; Morceau, F.; Dicato, M.; Diederich, M. Dietary compounds as potent inhibitors of the signal transducers and activators of transcription(STAT) 3 regulatory network. Genes Nutr., 2012, 7(2), 111-125.
33. Zhao, M.; Jiang, B.; Gao, F. H. Small molecule inhibitors of STAT3 for cancer therapy. Curr. Med. Chem., 2011, 18(26), 4012-4018.
34. Turkson, J.; Ryan, D.; Kim, J. S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.; Hamilton, A. D.; Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem., 2001, 276(48), 45443-45455.
35. Chakraborty, A.; Dyer, K. F.; Cascio, M.; Mietzner, T. A.; Tweardy, D. J. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood, 1999, 93(1), 15-24.
36. Coffer, P. J.; Kruijer, W. EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem. Biophys. Res. Commun., 1995, 210(1), 74-81.
37. Ren, Z.; Cabell, L. A.; Schaefer, T. S.; McMurray, J. S. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett., 2003, 13(4), 633-636.
38. Park, O. K.; Schaefer, L. K.; Wang, W.; Schaefer, T. S. Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms. J. Biol. Chem., 2000, 275(41), 32244-32249.
39. Stahl, N.; Farruggella, T. J.; Boulton, T. G.; Zhong, Z.; Darnell, J. E., Jr.; Yancopoulos, G. D. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science, 1995, 267(5202), 1349-1353.
40. Weber-Nordt, R. M.; Riley, J. K.; Greenlund, A. C.; Moore, K. W.; Darnell, J. E.; Schreiber, R. D. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem., 1996, 271(44), 27954-27961.
41. Malakhov, M. P.; Kim, K. I.; Malakhova, O. A.; Jacobs, B. S.; Borden, E. C.; Zhang, D. E. High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J. Biol. Chem., 2003, 278(19), 16608-16613.
42. Burke, T. R., Jr.; Yao, Z. J.; Liu, D. G.; Voigt, J.; Gao, Y. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers, 2001, 60(1), 32-44.
43. Burke, T. R., Jr.; Lee, K. Phosphotyrosyl mimetics in the development of signal transduction inhibitors. Acc. Chem. Res., 2003, 36(6), 426-433.
44. Hecker, S. J.; Erion, M. D. Prodrugs of phosphates and phosphonates. J. Med. Chem., 2008, 51(8), 2328-2345.
45. Chen, J.; Bai, L.; Bernard, D.; Nikolovska-Coleska, Z.; Gomez, C.; Zhang, J.; Yi, H.; Wang, S. Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. ACS Med. Chem. Lett., 2010, 1(2), 85-89.
46. Mandal, P. K.; Kaluarachchi, K. K.; Ogrin, D.; Bott, S. G.; McMurray, J. S. An efficient synthesis of the constrained peptidomimetic 2-oxo-3-(N-9-fluorenyloxycarbonylamino)-1-azabicyclo[ 4. 3. 0]nonane-9-carboxylic acid from pyroglutamic acid. J. Org. Chem., 2005, 70(24), 10128-10131.
47. Mandal, P. K.; Limbrick, D.; Coleman, D. R.; Dyer, G. A.; Ren, Z.; Birtwistle, J. S.; Xiong, C.; Chen, X.; Briggs, J. M.; McMurray, J. S. Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling. J. Med. Chem., 2009, 52(8), 2429-2442.
48. Mandal, P. K.; Gao, F.; Lu, Z.; Ren, Z.; Ramesh, R.; Birtwistle, J. S.; Kaluarachchi, K. K.; Chen, X.; Bast, R. C., Jr.; Liao, W. S.; McMurray, J. S. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2(SH2) domain of signal transducer and activator of transcription 3. J. Med. Chem., 2011, 54(10), 3549-3563.
49. Mandal, P. K.; Ren, Z.; Chen, X.; Kaluarachchi, K.; Liao, W. S.; McMurray, J. S. Structure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2(SH2) Domain of Signal Transducer and Activator of Transcription 3(Stat3). Int. J. Pept. Res. Ther., 2013, 19(1), 3-12.
50. Mandal, P. K.; Liao, W. S.; McMurray, J. S. Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3. Org. Lett., 2009, 11(15), 3394-3397.
51. McMurray, J. S.; Mandal, P. K.; Liao, W. S.; Klostergaard, J.; Robertson, F. M. The consequences of selective inhibition of signal transducer and activator of transcription 3(STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2(SH2) domain. JAKSTAT, 2012, 1(4), 263-347.
52. Gunning, P. T.; Katt, W. P.; Glenn, M.; Siddiquee, K.; Kim, J. S.; Jove, R.; Sebti, S. M.; Turkson, J.; Hamilton, A. D. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg. Med. Chem. Lett., 2007, 17(7), 1875-1878.
53. Morlacchi, P.; Mandal, P. K.; McMurray, J. S. Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor Targeting the Src Homology 2(SH2) Domain of STAT6. ACS Med. Chem. Lett., 2014, 5(1), 69-72.
54. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem., 2001, 276(8), 5836-5840.
55. Matsui, H.; Tomizawa, K.; Lu, Y. F.; Matsushita, M. Protein Therapy: in vivo protein transduction by polyarginine(11R) PTD and subcellular targeting delivery. Curr. Protein Pept. Sci., 2003, 4(2), 151-157.
56. Schwarze, S. R.; Dowdy, S. F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci., 2000, 21(2), 45-48.
57. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(24), 13003-13008.
58. Buerger, C.; Nagel-Wolfrum, K.; Kunz, C.; Wittig, I.; Butz, K.; Hoppe-Seyler, F.; Groner, B. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol. Chem., 2003, 278(39), 37610-37621.
59. Schwarze, S. R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285(5433), 1569-1572.
60. Williams, E. J.; Dunican, D. J.; Green, P. J.; Howell, F. V.; Derossi, D.; Walsh, F. S.; Doherty, P. Selective inhibition of growth factorstimulated mitogenesis by a cell-permeable Grb2-binding peptide. J. Biol. Chem., 1997, 272(35), 22349-22354.
61. Zolotarevsky, Y.; Hecht, G.; Koutsouris, A.; Gonzalez, D. E.; Quan, C.; Tom, J.; Mrsny, R. J.; Turner, J. R. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology, 2002, 123(1), 163-172.
62. Xu, X.; Sun, Y. L.; Hoey, T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT aminoterminal domain. Science, 1996, 273(5276), 794-797.
63. Zhang, X.; Darnell, J. E., Jr. Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J. Biol. Chem., 2001, 276(36), 33576-33581.
64. Zhang, Y.; Sif, S.; DeWille, J. The mouse C/EBPdelta gene promoter is regulated by STAT3 and Sp1 transcriptional activators, chromatin remodeling and c-Myc repression. J. Cell. Biochem., 2007, 102(5), 1256-1270.
65. Wang, Y.; Levy, D. E. Comparative evolutionary genomics of the STAT family of transcription factors. JAKSTAT, 2012, 1(1), 23-33.
66. Primiano, T.; Baig, M.; Maliyekkel, A.; Chang, B. D.; Fellars, S.; Sadhu, J.; Axenovich, S. A.; Holzmayer, T. A.; Roninson, I. B. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell, 2003, 4(1), 41-53.
67. Moriggl, R.; Sexl, V.; Kenner, L.; Duntsch, C.; Stangl, K.; Gingras, S.; Hoffmeyer, A.; Bauer, A.; Piekorz, R.; Wang, D.; Bunting, K. D.; Wagner, E. F.; Sonneck, K.; Valent, P.; Ihle, J. N.; Beug, H. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell, 2005, 7(1), 87-99.
68. Timofeeva, O. A.; Gaponenko, V.; Lockett, S. J.; Tarasov, S. G.; Jiang, S.; Michejda, C. J.; Perantoni, A. O.; Tarasova, N. I. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem. Biol., 2007, 2(12), 799-809.
69. Vinkemeier, U.; Moarefi, I.; Darnell, J. E., Jr.; Kuriyan, J. Structure of the amino-terminal protein interaction domain of STAT-4. Science, 1998, 279(5353), 1048-1052.
70. Johannessen, L.; Remsberg, J.; Gaponenko, V.; Adams, K. M.; Barchi, J. J., Jr.; Tarasov, S. G.; Jiang, S.; Tarasova, N. I. Peptide structure stabilization by membrane anchoring and its general applicability to the development of potent cell-permeable inhibitors. ChemBioChem., 2011, 12(6), 914-921.
71. Remsberg, J. R.; Lou, H.; Tarasov, S. G.; Dean, M.; Tarasova, N. I. Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. J. Med. Chem., 2007, 50(18), 4534-4538.
72. Bickle, M. B.; Dusserre, E.; Moncorge, O.; Bottin, H.; Colas, P. Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures. Nat. Protoc., 2006, 1(3), 1066-1091.
73. Borghouts, C.; Kunz, C.; Groner, B. Peptide aptamer libraries. Comb. Chem. High Throughput Screen. 2008, 11(2), 135-145.
74. Hoppe-Seyler, F.; Butz, K. Peptide aptamers: powerful new tools for molecular medicine. J. Mol. Med. (Berl.), 2000, 78(8), 426-430.
75. Hoppe-Seyler, F.; Crnkovic-Mertens, I.; Denk, C.; Fitscher, B. A.; Klevenz, B.; Tomai, E.; Butz, K. Peptide aptamers: new tools to study protein interactions. J. Steroid Biochem. Mol. Biol., 2001, 78(2), 105-111.
76. Ladner, R. C. Constrained peptides as binding entities. Trends Biotechnol., 1995, 13(10), 426-430.
77. Nagel-Wolfrum, K.; Buerger, C.; Wittig, I.; Butz, K.; Hoppe-Seyler, F.; Groner, B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol. Cancer Res., 2004, 2(3), 170-182.
78. Borghouts, C.; Delis, N.; Brill, B.; Weiss, A.; Mack, L.; Lucks, P.; Groner, B. A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells. JAKSTAT, 2012, 1(1), 44-54.
79. Kim, D.; Lee, I. H.; Kim, S.; Choi, M.; Kim, H.; Ahn, S.; Saw, P. E.; Jeon, H.; Lee, Y.; Jon, S. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res., 2014, 74(8), 2144-2151.
80. Kim, S.; Kim, D.; Jung, H. H.; Lee, I. H.; Kim, J. I.; Suh, J. Y.; Jon, S. Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides. Angew. Chem. Int. Ed. Engl., 2012, 51(8), 1890-1894.
81. McCusker, C. T.; Wang, Y.; Shan, J.; Kinyanjui, M. W.; Villeneuve, A.; Michael, H.; Fixman, E. D. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominantnegative STAT-6 peptide. J. Immunol., 2007, 179(4), 2556-2564.
82. Ho, A.; Schwarze, S. R.; Mermelstein, S. J.; Waksman, G.; Dowdy, S. F. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res., 2001, 61(2), 474-477.
83. Wang, Y.; Li, Y.; Shan, J.; Fixman, E.; McCusker, C. Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell-penetrating peptide. Clin. Exp. Allergy, 2011, 41(11), 1622-1630.
84. Weber, A.; Borghouts, C.; Brendel, C.; Moriggl, R.; Delis, N.; Brill, B.; Vafaizadeh, V.; Groner, B. The inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells. Pharmaceuticals (Basel), 2013, 6(8), 960-987.
85. Szelag, M.; Czerwoniec, A.; Wesoly, J.; Bluyssen, H. A. Comparative screening and validation as a novel tool to identify STATspecific inhibitors. Eur. J. Pharmacol., 2014, 740, 417-420.
86. Kim, M. J.; Nam, H. J.; Kim, H. P.; Han, S. W.; Im, S. A.; Kim, T. Y.; Oh, D. Y.; Bang, Y. J. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett., 2013, 335(1), 145-152.
87. Page, B. D.; Fletcher, S.; Yue, P.; Li, Z.; Zhang, X.; Sharmeen, S.; Datti, A.; Wrana, J. L.; Trudel, S.; Schimmer, A. D.; Turkson, J.; Gunning, P. T. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg. Med. Chem. Lett., 2011, 21(18), 5605-5609.
88. Sperl, B.; Seifert, M. H.; Berg, T. Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. Bioorg. Med. Chem. Lett., 2009, 19(12), 3305-3309.
89. Szelag, M.; Sikorski, K.; Czerwoniec, A.; Szatkowska, K.; Wesoly, J.; Bluyssen, H. A. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. Eur. J. Pharmacol., 2013, 720(1-3), 38-48.